Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease

Ashok Sriram, Herbert E. Ward, Anhar Hassan, Sanjay Iyer, Kelly D. Foote, Ramon L. Rodriguez, Nikolaus R. McFarland, Michael S. Okun

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

It has been previously well established that the use of dopaminergic agents in Parkinson's disease may contribute to behavioral disturbances such as dopamine dysregulation syndrome (DDS), impulse control disorders (ICD), and punding. ICD and punding have been most commonly addressed by reducing dose or by discontinuing the use of a dopamine agonist. Treatment of DDS has proven more challenging, and to date there has been no standard approach. In this paper, we review a series of four patients who met criteria for DDS, who were all refractory to medication adjustments. The DDS symptoms responded by the addition of valproic acid in all cases.

Original languageEnglish (US)
Pages (from-to)521-527
Number of pages7
JournalJournal of Neurology
Volume260
Issue number2
DOIs
StatePublished - Feb 1 2013

Keywords

  • Dominion
  • Dopamine dysregulation syndrome
  • Impulse control disorder
  • Parkinson's disease
  • Valproic acid

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this

    Sriram, A., Ward, H. E., Hassan, A., Iyer, S., Foote, K. D., Rodriguez, R. L., McFarland, N. R., & Okun, M. S. (2013). Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease. Journal of Neurology, 260(2), 521-527. https://doi.org/10.1007/s00415-012-6669-1